WallStreetZenWallStreetZen

NASDAQ: KZIA
Kazia Therapeutics Ltd Stock Forecast, Predictions & Price Target

OverviewForecast
EarningsRevenueDividendOwnership

Analyst price target for KZIA

Based on 3 analysts offering 12 month price targets for Kazia Therapeutics Ltd

Min Forecast
$13.00+71.05%
Avg Forecast
$16.00+110.53%
Max Forecast
$20.00+163.16%

Should I buy or sell KZIA stock?

Based on 3 analysts offering ratings for Kazia Therapeutics Ltd.

Strong Buy
Strong Buy
2 analysts 66.67%
Buy
1 analysts 33.33%
Hold
0 analysts 0%
Sell
0 analysts 0%
Strong Sell
0 analysts 0%

Be the first to know when Wall Street analysts revise their KZIA stock forecasts and price targets.

KZIA stock forecasts by analyst

Analyst / FirmRatingActionPrice TargetUpside/DownsideDateAnalyst Color
lockedlocked$00.00+00.00%2025-10-02
lockedlocked$00.00+00.00%2025-07-10
lockedlocked$00.00+00.00%2025-06-11

1 of 1

Forecast return on equity

Is KZIA forecast to generate an efficient return?

Insufficient data to display

Forecast return on assets

Is KZIA forecast to generate an efficient return on assets?

Company
-30,182.65%
Industry
98.92%
KZIA is forecast to generate... subscribe to Premium to read more.
Forecast Return on Assets vs Industry Forecast

KZIA earnings per share forecast

What is KZIA's earnings per share in the next 3 years based on estimates from 4 analysts?

Avg 1 year Forecast
-$1.44
Avg 2 year Forecast
-$1.53
Avg 3 year Forecast
-$1.47

KZIA revenue forecast

What is KZIA's revenue in the next 3 years based on estimates from 4 analysts?

Avg 1 year Forecast
$51.0k-95.76%
Avg 2 year Forecast
$31.1k-97.41%
Avg 3 year Forecast
$1.0M-16.15%
KZIA's revenue is forecast to... subscribe to Premium to read more.
Forecast High Revenue Growth Forecast

KZIA revenue growth forecast

How is KZIA forecast to perform vs Biotechnology companies and vs the US market?

Company
-10.81%
Industry
104.25%
Market
25.69%
KZIA's revenues are forecast to... subscribe to Premium to read more.
Forecast Revenue Growth vs Industry Forecast
KZIA's revenues are forecast to... subscribe to Premium to read more.
Forecast Revenue Growth vs Market Forecast

KZIA vs Biotech Stocks

TickerPricePrice TargetUp/downsideConsensus
KZIA$7.66$16.00+108.88%Strong Buy
VOR$9.84$41.33+320.05%Buy
OSTX$1.89$20.00+958.20%Strong Buy
INKT$13.23$35.00+164.55%Buy
ANL$1.62N/AN/A
View Top Biotech Stocks

Kazia Therapeutics Stock Forecast FAQ

Is Kazia Therapeutics Stock a good buy in 2025, according to Wall Street analysts?

The consensus among 3 Wall Street analysts covering (NASDAQ: KZIA) stock is to Strong Buy KZIA stock.

Out of 3 analysts, 2 (66.67%) are recommending KZIA as a Strong Buy, 1 (33.33%) are recommending KZIA as a Buy, 0 (0%) are recommending KZIA as a Hold, 0 (0%) are recommending KZIA as a Sell, and 0 (0%) are recommending KZIA as a Strong Sell.

If you're new to stock investing, here's how to buy Kazia Therapeutics stock.

What is KZIA's earnings growth forecast for 2026-2028?

(NASDAQ: KZIA) Kazia Therapeutics's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 47.94%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 42.59%.

Kazia Therapeutics's earnings in 2025 is -$13,442,857.On average, 4 Wall Street analysts forecast KZIA's earnings for 2026 to be -$1,168,234,059, with the lowest KZIA earnings forecast at -$1,451,611,558, and the highest KZIA earnings forecast at -$849,889,671. On average, 3 Wall Street analysts forecast KZIA's earnings for 2027 to be -$1,238,410,663, with the lowest KZIA earnings forecast at -$1,189,845,539, and the highest KZIA earnings forecast at -$1,274,834,506.

In 2028, KZIA is forecast to generate -$1,187,902,934 in earnings, with the lowest earnings forecast at -$1,141,280,415 and the highest earnings forecast at -$1,222,788,881.

What is KZIA's revenue growth forecast for 2026-2028?

(NASDAQ: KZIA) Kazia Therapeutics's forecast annual revenue growth rate of -10.81% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 104.82%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 25.65%.

Kazia Therapeutics's revenue in 2025 is $1,187,662.On average, 4 Wall Street analysts forecast KZIA's revenue for 2026 to be $41,280,355, with the lowest KZIA revenue forecast at $0, and the highest KZIA revenue forecast at $84,988,967. On average, 4 Wall Street analysts forecast KZIA's revenue for 2027 to be $25,181,017, with the lowest KZIA revenue forecast at $0, and the highest KZIA revenue forecast at $51,843,270.

In 2028, KZIA is forecast to generate $816,703,503 in revenue, with the lowest revenue forecast at $0 and the highest revenue forecast at $1,681,972,129.

What is KZIA's forecast return on assets (ROA) for 2026-2028?

(NASDAQ: KZIA) forecast ROA is -30,182.65%, which is lower than the forecast US Biotechnology industry average of 94.59%.

What is KZIA's Price Target?

According to 3 Wall Street analysts that have issued a 1 year KZIA price target, the average KZIA price target is $16.00, with the highest KZIA stock price forecast at $20.00 and the lowest KZIA stock price forecast at $13.00.

On average, Wall Street analysts predict that Kazia Therapeutics's share price could reach $16.00 by Oct 2, 2026. The average Kazia Therapeutics stock price prediction forecasts a potential upside of 108.88% from the current KZIA share price of $7.66.

What is KZIA's Earnings Per Share (EPS) forecast for 2026-2028?

(NASDAQ: KZIA) Kazia Therapeutics's current Earnings Per Share (EPS) is -$2.46. On average, analysts forecast that KZIA's EPS will be -$1.44 for 2026, with the lowest EPS forecast at -$1.79, and the highest EPS forecast at -$1.05. On average, analysts forecast that KZIA's EPS will be -$1.53 for 2027, with the lowest EPS forecast at -$1.47, and the highest EPS forecast at -$1.58. In 2028, KZIA's EPS is forecast to hit -$1.47 (min: -$1.41, max: -$1.51).

What is KZIA's forecast return on equity (ROE) for 2026-2028?

(NASDAQ: KZIA) forecast ROE is N/A, which is considered weak.
©2025 WallStreetZen
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletter
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.